Skip to ContentSkip to Navigation
Practical matters How to find us prof. dr. M. (Michiel) Rienstra

Research interests

Michiel Rienstra graduated in medicine (cum laude) at the University of Antwerp, Belgium in 2003, graduated master of health administration in 2021 at TIAS School for Business and Society, The Netherlands. Obtained a PhD at the University of Groningen, The Netherlands in 2007 on Atrial Fibrillation, Underlying Disease and Prognosis. He completed his cardiology training at the University Medical Center Groningen in 2012, followed by training as device cardiologist, where continued working as clinical cardiologist and researcher. He is a Professor of Clinical Cardiology at the University of Groningen, past-Clinical Director of the Department of Cardiology, and cardiologist at the University Medical Center Groningen, specialized in AF, devices and advanced HF. He combines treatment of patients with arrhythmias and HF with clinic-oriented AF and HF research. He is founder of the regional network HeartNet Northern-Netherlands (since 2018) aiming to integrate care and value-based heath care for inhabitants at risk and patients with cardiovascular diseases in the 2 Northern provinces of the Netherlands. Stakeholders of the network are patient organisations, cardiologists, general practitioner cooperation’s, and health insurance companies. His research consists of conducting investigator-initiated clinical studies to improve AF or HF treatment (steeringcie/principal investigator of RACE I to V, CONVERT, VIP-HF, MARC, DECISION, RACE 7-ACWAS, DUTCH-AF), studying epidemiology of AF and its risk factors (including HF) in PREVEND, Lifelines and Framingham Heart Study, uncovering the genetics of AF in part with the AFGen international consortium (contributor since NWO-Rubicon fellowship in Boston), and applying novel bioinformatics tools to improve AF risk prediction using biobanks of AF patients (AF-Risk, Biomarker-AF, Young-AF). He was awarded with a NWO-VENI grant for a project on genetics of AF, followed by European Society of Cardiology academic grant for a project on a big data approach in AF. He is involved in several national consortia (Cardiovascular Research Netherlands - CVON): CVON-RACE V (hypercoagulability and AF progression), CVON-RED-CVD (early detection of cardiovascular disease in general practices), and CVON-AI (Catalyzing the application of Artificial Intelligence for Cardiovascular Research Netherlands), and co-PI of the DECISION (Digoxin Evaluation in Chronic Heart Failure: Investigational Study in Outpatients in the Netherlands), and steering committee member of numerous investigator-initiated studies (RACE 8, RACE 9, MARC 2 and CABA-HFPEF). He is PI of the national AF-network EmbRACE in the Netherlands. He is fellow of the European Society of Cardiology and the American Heart Association. He is research coordinator for the European Society of Cardiology 2024 guidelines on management of AF.


Research consists of conducting clinical studies and trials to improve AF treatment, also in the setting of HF; studying the epidemiology of AF and its risk factors (with emphasis on HF) in PREVEND, Lifelines; uncvering the genetics of AF within the international AFGen/TOPMED consortia; and applying bioinformatics/machine learning/artificial intelligence tools to improve AF risk prediction.

Read more


Atrial fibrillation and heart failure temporality: does it matter?

Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study

Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference

Mobile health adherence for the detection of recurrent recent-onset atrial fibrillation

Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation

Sex Differences in Early Rhythm Control of Atrial Fibrillation in the EAST-AFNET 4 Trial

A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?

A saturated map of common genetic variants associated with human height

Assessment of sex-related differences and outcome in patients who underwent cryoballoon pulmonary vein isolation for atrial fibrillation: an observational cohort study

Association between comorbidities and left and right atrial dysfunction in patients with paroxysmal atrial fibrillation: Analysis of AF-RISK

Read more


Grootschalig onderzoek naar boezemfibrilleren

€2,5 miljoen subsidie Hartstichting voor onderzoek UMCG

Hartstichting geeft €2,5 miljoen subsidie voor boezemfibrilleren-onderzoek

€2,5 miljoen subsidie Hartstichting voor boezemfibrilleren-onderzoek

2,5 miljoen euro voor eerder en beter behandelen van boezemfibrilleren

€2,5 miljoen subsidie Hartstichting voor boezemfibrilleren-onderzoek

Targeted therapy effect on sinus rhythm in early AF may not stand the test of time

Vorhofflimmern: Kann Risikofaktor-Management Sinusrhythmus erhalten?

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

Read more